Cargando…
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
BACKGROUND: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. M...
Autores principales: | Magro, Fernando, Lopes, Susana, Silva, Marco, Coelho, Rosa, Portela, Francisco, Branquinho, Diogo, Correia, Luís, Fernandes, Samuel, Cravo, Marília, Caldeira, Paulo, Tavares de Sousa, Helena, Patita, Marta, Lago, Paula, Ramos, Jaime, Afonso, Joana, Redondo, Isabel, Machado, Patrícia, Philip, George, Lopes, Joanne, Carneiro, Fátima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719471/ https://www.ncbi.nlm.nih.gov/pubmed/31516554 http://dx.doi.org/10.1177/1756284819869141 |
Ejemplares similares
-
Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014) -
Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014) -
Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019) -
Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017) -
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)